UDR to Participate in Upcoming Real Estate Conferences

DENVER--(BUSINESS WIRE)-- UDR, Inc. (the “Company”) (NYSE: UDR), a leading multifamily real estate investment trust, announced today that the Company will participate in the Evercore ISI Real Estate Conference on September 4 and the Bank of America Securities 2025 Global Real Estate Conference on September 9-11, 2025.

At the Bank of America Securities Conference, the UDR Executive Team will host a roundtable discussion on Tuesday, September 9, 2025, at 3:00 p.m. Eastern Time. This discussion will be made available as a webcast that can be accessed at https://bofa.veracast.com/webcasts/bofa/realestate2025/e7ge0e.cfm as well as on the Investor Relations section of the Company’s website at ir.udr.com. A replay of the roundtable will be available for 90 days on the Company’s website.

A copy of materials to be provided by the Company at these conferences was recently published and is available on the Investor Relations section of the Company’s website, under “Presentations & Webcasts.”

About UDR, Inc.

UDR, Inc. (NYSE: UDR), an S&P 500 company, is a leading multifamily real estate investment trust with a demonstrated performance history of delivering superior and dependable returns by successfully managing, buying, selling, developing and redeveloping attractive real estate properties in targeted U.S. markets. As of June 30, 2025, UDR owned or had an ownership position in 60,535 apartment homes, including 300 apartment homes under development. For over 53 years, UDR has delivered long-term value to shareholders, the best standard of service to residents and the highest quality experience for associates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250902252163/en/

UDR, Inc.
Trent Trujillo
[email protected]
720-283-6135

Source: UDR, Inc.

You May Also Be Interested In

• Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
• Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine
• Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and